BWAY
Brainsway Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Brainsway Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Brainsway Ltd.
11.30
−0.63 · −5.29%
post 11.30 0.00%
No changes.
No changes.
No peers for Brainsway Ltd. yet.
No peers for Brainsway Ltd. yet.
Annual filing, covered
20-F parsed · Apr 20 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Apr 20 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
—
News
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| Valor | $82.4M | 46.55% | 0.00% |
| Masters | $23.3M | 13.14% | −9.09% |
| Acadian | $12.5M | 7.08% | −1.26% |
| Essex | $9.2M | 5.19% | −4.19% |
| Renaissance Technologies | $7.4M | 4.17% | −8.20% |
| Manager | Value | % base | |
|---|---|---|---|
| Valor | $82.4M | 46.55% | 0.00% |
| Masters | $23.3M | 13.14% | −9.09% |
| Acadian | $12.5M | 7.08% | −1.26% |
| Essex | $9.2M | 5.19% | −4.19% |
| Renaissance Technologies | $7.4M | 4.17% | −8.20% |